Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network. (April 2022)

• Record Type: Journal Article
• Authors: Robert, Nicholas J.; Espirito, Janet L.; Chen, Liwei; Nwokeji, Esmond; Karhade, Mandar; Evangelist, Makenzi; Spira, Alexander; Neubauer, Marcus; Bullock, Susie; Walberg, Jennifer; Cheng, Steven K.; Coleman, Robert L.
• Is Part Of: Lung cancer. Volume 166(2022)
• Page Start: 197
• Page End: 204
• Publication Date: 2022-04
• Subjects: 1L first-line therapy -- cfDNA cell-free DNA -- EHR electronic health record -- IQR interquartile -- MYLUNG Molecularly Informed Lung Cancer Treatment in a Community Cancer Network -- NGS next-generation sequencing -- SD standard deviation; NSCLC -- Biomarker testing -- Next-generation sequencing; Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2022.03.004
• Languages: English
• ISSNs: 0169-5002

Abstract

Highlights: MYLUNG analyzed biomarker testing in metastatic NSCLC in community-based oncology practices. Median time from diagnosis to 1L treatment initiation was approximately 5 weeks. Turnaround time from test orders to results availability was approximately 2 weeks. Only 35% had test results before first-line treatment initiation for all 5 biomarkers. NGS testing rates increased with time but remained below 50% over the study period. Abstract: Objectives: The MYLUNG (Molecularly Informed Lung Cancer Treatment in a Community Cancer Network) consortium pragmatic study assessed real-world biomarker testing rates and turnaround times within a large community-based oncology network. Materials and Methods: This retrospective observational chart review study investigated patients with mNSCLC initiating first-line (1L) systemic therapy between 01-April-2018 and 31-March-2020. Biomarker testing rates and timing relative to 1L therapy for EGFR, ALK, ROS1, BRAF, and PD-L1 were assessed, including use of next-generation sequencing (NGS). Results: Among 3474 adults: 74% had adenocarcinoma and 76% had a documented ECOG performance status of 0 or 1. Ninety percent had testing for at least one biomarker, and 46% received all 5 biomarker tests. Changes in testing rates from 2018 to 2020 were 71% to 71% for EGFR, 71% to 70% for ALK, 69% to 67% for ROS1, 51% to 59% for BRAF, 82% to 84% for PD-L1, and 42% to 49% for all 5 biomarkers. NGS testing increased from 33% to 45% (p < 0.0001). Median time from mNSCLC diagnosis to 1L therapy was 35 days. Median turnaround times from biomarker testing orders to results ranged from 10 to 15 days for the individual biomarkers and 18 days for NGS. Conclusion: In this real-world study, while most patients received at least one biomarker test prior to 1L, <50% received all 5 tests. NGS testing also occurred in < 50% of patients but appeared to increase over time. The next phase of MYLUNG will evaluate contemporary ordering practices and turnaround times prospectively.